2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-135883
    PKR activator 1 2283420-62-0 98%
    PKR activator 1 is a potent pyruvate kinase-R (PKR) activator extracted from patent WO2019035865A1, compound E7-93.
    PKR activator 1
  • HY-136346
    2-Hydroxy atorvastatin lactone 163217-74-1 98%
    2-Hydroxy atorvastatin lactone is a metabolite of Atorvastatin. Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids.
    2-Hydroxy atorvastatin lactone
  • HY-136584
    2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid 413624-71-2 ≥98.0%
    2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid is a ketone compound extracted from patent WO2002030860A2, compound example II-9. 2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid can be used for the research of cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders.
    2,2,14,14-Tetramethyl-8-oxopentadecanedioic acid
  • HY-141530
    Clopidogrel-β-D-glucuronide 1314116-53-4 98%
    Clopidogrel-β-D-glucuronide is a metabolite of Clopidogrel (HY-15283). Clopidogrel-β-D-glucuronide directly interacts with CYP2C8 enzyme and strongly inhibits the liver enzyme CYP2C8.
    Clopidogrel-β-D-glucuronide
  • HY-141581
    Lyso-PAF C-18 74430-89-0 ≥98.0%
    Lyso-PAF C-18 is an intermediate for the synthesis of C18-PAF (HY-130345). It has an easily substituted "Lyso-PAF" structure and is easy to purify and has high yield. C18-PAF is a ligand for platelet-activating factor and PAF G protein-coupled receptor (PAFR) and has renovasodilator properties and antihypertensive lipid properties.
    Lyso-PAF C-18
  • HY-14184S
    Macitentan-d4 1258428-05-5 98.03%
    Macitentan-d4 is a deuterium labeled Sulfamethoxazole. Macitentan is an orally active, non-peptide dual ETA and ETB (endothelin) receptor antagonist. Macitentan has the potential for idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Macitentan-d4
  • HY-14188R
    Amiodarone hydrochloride (Standard) 19774-82-4
    Amiodarone (hydrochloride) (Standard) is the analytical standard of Amiodarone (hydrochloride). This product is intended for research and analytical applications. Amiodarone hydrochloride, a benzofuran-based Class III antiarrhythmic agent, inhibits WT outwardIhERG tails with an IC50 of ∼45 nM. Amiodarone hydrochloride induces cell proliferation and myofibroblast differentiation via ERK1/2 and p38 MAPK signaling in fibroblasts. Amiodarone hydrochloride can be used in the research of both supraventricular and ventricular arrhythmias.
    Amiodarone hydrochloride (Standard)
  • HY-145992
    KCNQ1 activator-1 1008671-38-2 99.03%
    KCNQ1 activator-1 (compound 3) is a potent activator of KCNQ1 channel. KCNQ1 activator-1 has the potential for the research of long QT syndrome (LQTS).
    KCNQ1 activator-1
  • HY-14664C
    (3S,5R)-Fluvastatin sodium 94061-81-1 98.16%
    (3S,5R)-Fluvastatin sodium ((3S,5R)-XU 62-320) is the (3S,5R)-enantiomer of Fluvastatin. Fluvastatin is a first fully synthetic, competitive HMG-CoA reductase inhibitor with an IC50 of 8 nM. Fluvastatin protects vascular smooth muscle cells against oxidative stress through the Nrf2-dependent antioxidant pathway.
    (3S,5R)-Fluvastatin sodium
  • HY-147005
    piCRAC-1 2418049-54-2 98.24%
    piCRAC-1 is a potent, photoinducible Ca2+ release-activated Ca2+ (CRAC) channel inhibitor. piCRAC-1 alleviates thrombocytopenia and hemorrhage.
    piCRAC-1
  • HY-147079
    Egaptivon pegol 934868-74-3
    Egaptivon pegol (ARC1779) is an aptamer, which blocks binding of the von Willebrand Factor (VWF) to platelet GPIb receptors. Egaptivon pegol has anti-thrombotic efficacy.
    Egaptivon pegol
  • HY-147300
    Puliginurad 2013582-27-7 99.96%
    Puliginurad (YL-90148) is a potent urate transporter (URAT) inhibitor. Puliginurad can be used for hyperuricemia and gout research.
    Puliginurad
  • HY-147384
    CXL-1020 950834-06-7 ≥99.0%
    CXL-1020 is a hydroxylamine-based nitroxyl (HNO) donor. CXL-1020 improves cardiac inotropy/lusitropy and Ca2+ cycling in rats with abnormal relaxation. CXL-1020 induces vasorelaxation and improves cardiac function in canine models. CXL-1020 has been used to research systolic heart failure and stable heart failure.
    CXL-1020
  • HY-14779S
    Riociguat-13C,d6 ≥99.0%
    Riociguat-13C,d6 is the 13C and deuterium labeled Riociguat (HY-14779). Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
    Riociguat-13C,d6
  • HY-14806S
    Teneligliptin-d8 1391012-95-5 98%
    Teneligliptin-d8 is a deuterium labeled Teneligliptin (MP-513). Teneligliptin is a potent, orally available, competitive, and long-lasting DPP-4 inhibitor.
    Teneligliptin-d8
  • HY-148147
    Metamizole 50567-35-6 98%
    Metamizol (Methamizole) is an anti-thyroid agent, which blocks thyroid hormone production from the thyroid gland. Metamizol can cause hepatotoxicity.
    Metamizole
  • HY-148529
    Midaglizole 66529-17-7 98.28%
    Midaglizole ((±)-DG5128 free base, DG5128 free base) is a potent α2-adrenoceptor antagonist. Midaglizole is a hypoglycemic agent. Midaglizole increases blood pressure and reduces blood glucose levels in vivo.
    Midaglizole
  • HY-148908
    TNF-α-IN-8 444287-85-8
    TNF-α-IN-8 (compound I-42) is a TNF-α inhibitor. TNF-α-IN-8 is an isoindole-imide compound. TNF-α-IN-8 can be used for the research of cancer, heart disease, osteoporosis, inflammatory, allergic and autoimmune diseases. TNF-α-IN-8 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.
    TNF-α-IN-8
  • HY-151369
    AV123 233605-81-7 99.60%
    AV123 (compound 12) is a non-cytotoxic RIPK1 inhibitor (IC50=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC50=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases.
    AV123
  • HY-152086
    DRP1i27 1453028-33-5 98.73%
    DRP1i27 is a potent inhibitor of human Drp1 (dynamin-related protein 1). DRP1i27 binds to the GTPase site of Drp1, with hydrogen bonds to Gln34 and Asp218. DRP1i27 targets Drp1-mediated mitochondrial fission in cell line models and protects against simulated ischemia-reperfusion injury.
    DRP1i27
Cat. No. Product Name / Synonyms Application Reactivity